| Biomarker ID | 357 |
| PMID | 18559597 |
| Year | 2008 |
| Biomarker | uPA receptor (uPAR) |
| Biomarker Basis | Concentration Based (ng/ml) |
| Biomolecule | Protein |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Increased with Biochemical Recurrence |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: (Rate Ratio: 2.17); Multivariate: (Rate Ratio: 1.40) |
| Effect on Pathways | Pathways Include:- Beta-3 integrin cell surface interactions,Dissolution of fibrin clot,Post-translational modification: biosynthesis of GPI-anchored proteins,Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling, Integrin beta-5 pathway |
| Experiment | Biochemical Recurrence Vs no Recurrence in 5 years |
| Type of Biomarker | Prognostic |
| Cohort | 423 patients treated with radical prostatectomy and bilateral lymphadenectomy for clinically localized prostatic adenocarcinoma were chosen. |
| Senstivity | NA |
| Specificity | NA |
| AUC | Univariate: Concordance Index: 62.4; Multivariate: Concordance Index: 70.9 |
| Accuracy | NA |
| Level Of Significance | Univariate: p<0.001; Multivariate: p=0.05 |
| Method Used | enzyme immunoassays |
| Clinical | No |
| Remarks | Univariate Analysis. Biochemical recurrence was defined as a sustained elevation, on two or more occasions, of serum total prostate-specific antigen >0.2 ng/mL |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | PLAUR |